Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 4/20 | 0.34 |
| ▸ | S100A4 | P26447 | 1/20 | 0.33 |
| ▸ | PGR | P06401 | 4/20 | 0.32 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.31 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
| ▸ | CMA1 | P23946 | 1/20 | 0.31 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15614861 | 0.79 | BACE2 (0.33) | AHRKDM1ABACE1CMA1 | |
| SCHEMBL15428014 | 0.75 | AHR (0.35) | AHR | |
| SCHEMBL17486216 | 0.75 | MAPK1 (0.37) | PGRBACE1 | |
| SCHEMBL24701899 | 0.74 | TDP1 (0.39) | PDK2CYP2A6 | |
| SCHEMBL12721438 | 0.73 | CYP2A6 (0.35) | AHRS100A4KDM1APDK2CMA1 | |
| SCHEMBL20212018 | 0.73 | CYP2A6 (0.35) | AHRS100A4KDM1APDK2CMA1 | |
| SCHEMBL6848342 | 0.73 | ALDH1A1 (0.36) | PDK2BACE1 | |
| SCHEMBL10819304 | 0.73 | HCAR3 (0.36) | PGRPDK2BACE1 | |
| SCHEMBL6770223 | 0.72 | PGR (0.54) | AHRPGRCMA1 | |
| SCHEMBL15614853 | 0.72 | KDM1A (0.36) | AHRKDM1ABACE1CMA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11917901-B2 | Metal complexes | UDC IRELAND LIMITED (IE) | 2024-02-27 | — | — | US | disclosed |
| US-11917901-B2 | Metal complexes | UDC IRELAND LIMITED (IE) | 2024-02-27 | — | — | US | disclosed |
| US-11005050-B2 | Metal complexes | MERCK PATENT GMBH (DE) | 2021-05-11 | — | — | US | disclosed |
| EP-3424936-B1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2021-04-07 | — | — | EP | disclosed |
| EP-3424936-A1 | METAL COMPLEXES | Merck Patent GmbH (DE) | 2019-01-09 | — | — | EP | disclosed |
| EP-3094638-B1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2017-11-08 | — | — | EP | disclosed |
| US-20170170413-A1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2017-06-15 | — | — | US | disclosed |
| US-20170170413-A1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2017-06-15 | — | — | US | disclosed |
| US-20160365520-A1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2016-12-15 | — | — | US | disclosed |
| US-20160365520-A1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2016-12-15 | — | — | US | disclosed |
| US-20150171348-A1 | Metal Complexes | MERCK PATENT GMBH (DE) | 2015-06-18 | — | — | US | disclosed |
| WO-2014023377-A2 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2014-02-13 | — | — | WO | disclosed |
| US-7476673-B2 | Disubstituted chalcone oximes as selective agonists of RARγ retinoid receptors | ALLERGAN, INC. (US) | 2009-01-13 | — | — | US | disclosed |
| US-7476673-B2 | Disubstituted chalcone oximes as selective agonists of RARγ retinoid receptors | ALLERGAN, INC. (US) | 2009-01-13 | — | — | US | disclosed |
| CN-1320599-A | Limited 9-cis-isotretinoins | AMERICAN CYANAMID CO (US) | 2001-11-07 | — | — | CN | disclosed |
| EP-0718285-B1 | Restricted 9-cis-retinoids | AMERICAN CYANAMID CO (US) | 2001-04-11 | — | — | EP | disclosed |
| EP-0997455-A1 | Restricted 9-cis retenoids | American Cyanamid Company (US) | 2000-05-03 | — | — | EP | disclosed |
| US-5968908-A | Restricted 9-cis retinoids | AMERICAN CYANAMID COMPANY (US) | 1999-10-19 | — | — | US | disclosed |
| CN-1176248-A | Restricted 9-CIS-retinoids | AMERICAN CYANAMID CO (US) | 1998-03-18 | — | — | CN | disclosed |
| EP-0718285-A2 | Restricted 9-cis-retinoids | American Cyanamid Company (US) | 1996-06-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150171348-A1 | Metal Complexes | SOD1, AP1M1, AP3M1 | AHR 3359/4885S100A4 753/4885PGR 3351/4885 |
| US-11005050-B2 | Metal complexes | SOD1, AP1M1, AP3M1 | AHR 3359/4885S100A4 753/4885PGR 3351/4885 |
| US-20160365520-A1 | METAL COMPLEXES | SOD1, AP1M1, AP3M1 | AHR 3359/4885S100A4 753/4885PGR 3351/4885 |
| US-20170170413-A1 | METAL COMPLEXES | SOD1, AP1M1, AP3M1 | AHR 3359/4885S100A4 753/4885PGR 3351/4885 |
| US-11917901-B2 | Metal complexes | MCOLN2, MCOLN1, AP1M1 | AHR 4105/4885S100A4 745/4885PGR 3528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.